1
ALL1
AguettantYear
1
ALL1
2021DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
U.S.A1
ALL1
AcelRx PharmaceuticalsTherapeutic Area
1
ALL1
NeurologyStudy Phase
1
ALL1
ApprovedDeal Type
1
ALL1
Licensing AgreementProduct Type
1
ALL1
Small moleculeDosage Form
1
ALL1
Sublingual TabletLead Product
1
ALL1
Sufentanil CitrateTarget
1
ALL1
Mu opioid receptorLead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : AcelRx Pharmaceuticals
Deal Size : $55.0 million
Deal Type : Licensing Agreement
Details : Under the DZUVEO licensing agreement, Aguettant will have the right to commercialize DZUVEO in Europe. In 2018, AcelRx received approval for DZUVEO from the European Commission for use in medically monitored settings.
Brand Name : Dzuveo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 14, 2021
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : AcelRx Pharmaceuticals
Deal Size : $55.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?